ESSA is committed to improving the lives for patients with prostate cancer. We aim to do this through partnership: by listening to patients, our supporters, and advocacy communities. Our goal is to provide patient access to our investigational therapies at an appropriate time in the drug development process.

ESSA believes that investigational drugs should be primarily evaluated in patients as part of clinical trials that are designed to obtain data on drug safety and efficacy. Regulators will only authorize a new medicine if these trials, together with other research data, demonstrate that the medicine has a favorable risk benefit profile when used in a defined and controlled clinical setting. We encourage patients to speak with their physicians and to participate in clinical trials, when appropriate and if eligible.

ESSA recognizes that not every patient who wishes to participate in a clinical trial will meet the eligibility criteria. In rare cases when patients with serious diseases are unable to participate in clinical trials and have exhausted all available therapies, ESSA may consider providing an investigational drug outside of a clinical trial.